Search the GHTC website

Global health R&D delivers for Nebraska

US government investment in global health R&D has delivered

$51.5 million
to Nebraska research institutions
650+ new jobs
for Nebraska
Nebraska's top USG-funded global health R&D institutions

Nebraska's top USG-funded global health R&D institutions

University of Nebraska Medical Center
$30.9 million
Creighton University
$8.9 million
University of Nebraska-Lincoln
$6.4 million
$5.3 million

Nebraska's top areas of global health R&D by USG funding

Diarrheal diseases
Flioviral diseases (including Ebola, Marburg)
Neglected tropical diseases
Helminth infections (Worms & Flukes)
Reproductive health
Salmonella infections
Hepatitis B
Global health R&D at work in Nebraska

University of Nebraska Medical Center (UNMC) researchers are advancing a dual gene-editing approach that holds promise to eliminate HIV infection. Using the gene-editing tool CRISPR, scientists developed a therapy that targets both HIV-1, the most common virus that causes AIDS, and a protein on the surface of white blood cells called CCR5, which acts as a receptor allowing the virus to enter cells. By combining this gene therapy with another technology developed at UNMC called LASER ART (long-acting slow effective release antiviral therapy)—a type of injectable drug with an altered chemical structure that enables its slow release and thus better ability to reach body tissue where HIV can hide—the research team was able to eliminate HIV in animal studies. While still in the early stages, this research could one day lead to a cure for AIDS. Globally, more than 38 million people are living with HIV.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: NIAID/NIH